Name: Balicatib
Price: 289.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Balicatib is an inhibitor of cathepsin K with IC50 value of 1.4nM [1].Balicatib is highly selective against cathepsin K over cathepsin B, L and S in the in vitro enzyme assay. However, the selectivity is not so high in cell-based enzyme assay. The lysosomotropic character of balicatib results in its accumulation in lysosomes and the subsequent nonselective off-target effects. The off-target effects also cause the skin adverse events of balicatib [1, 2]. As a cathepsin K inhibitor, balicatib is developed for osteoporosis. It has been reported to reduce the biochemical markers of bone resorption and increase bone mineral density in ovariectomized monkeys. In addition, balicatib shows benefits in new bone formation of postmenopausal women [2].
    
    [1] Black WC. Peptidomimetic inhibitors of cathepsin K. 2010;10(7):745-51.
    [2] Brömme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs. 2009 May;18(5):585-600.
- Properties
  - Alternative Name
    
    N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide
    
    CAS Number
    
    354813-19-7
    
    Molecular Formula
    
    C23H33N5O2
    
    Molecular Weight
    
    411.54
    
    Appearance
    
    A solid
    
    Purity
    
    98.00%
    
    Solubility
    
    <2.30 mg/mL in EtOH insoluble in; ≥17 mg/mL in DMSO; insoluble in H2O
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

Balicatib

Balicatib

Background

We Also Recommend

AHU-377 hemicalcium salt

AMG 487

TAK-593